Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.55 |
| ▸ | CDC25B | P30305 | 12/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.55 |
| ▸ | CDC25A | P30304 | 3/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12812854 | 0.87 | NT5E (0.51) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL14001397 | 0.86 | PTPN1 (0.50) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL12612570 | 0.86 | PTPN1 (0.50) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL5840884 | 0.86 | TP53 (0.55) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL5840927 | 0.86 | TP53 (0.55) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL16967451 | 0.86 | TP53 (0.55) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL15514084 | 0.86 | TP53 (0.55) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL15513814 | 0.86 | NT5E (0.53) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL30980693 | 0.84 | PTPN1 (0.47) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL7582210 | 0.83 | TP53 (0.55) | PTPN1CDC25BPTPN2PTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073589-A1 | Amphetamine Prodrugs | SHIRE AG (CH) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073589-A1 | Amphetamine Prodrugs | SLC6A2, SLC6A3, TAAR5 | PTPN1 1433/4885CDC25B 1566/4885PTPN2 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.